Russian Academy of Sciences spinout PM&HM has signed up a second government-owned vehicle to help commercialise its digitally-enabled inhaler for tuberculosis, cancer and HIV.

Personal Medication and Health Management (PM&HM), a Russia-based connected inhaler system developer based on Russian Academy of Sciences research, has received 305m rubles ($4.6m) of funding, according to East-West Digital News.
The capital came from the National Technology Initiative Support Fund, an investment vehicle established by Russian government-owned fund-of-funds RVC.
PM&HM is developing a digitally-enabled inhaler for tuberculosis, cancer and HIV that comes with a fingerprint identifier, removable medication cartridge and telemedicine communication capabilities to help clinicians monitor…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?